Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Bioresorbable Scaffold Thrombosis: incidence, risk factors and possible mechanism

Original Title: Bioresorbable Vascular Scaffold Thrombosis. Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. Reference: Puricel S et al. J Am Coll Cardiol 2016;67:921-31.

Courtesy of Dr. Guillermo Migliaro.

Bioresorbable scaffolds (BVS) were introduced in interventional cardiology to avoid late DES complications. However, recent reports suggest an elevated incidence of thrombosis with these new devices.

The referred article is a registry carried out in 4 centers including 1305 consecutive patients undergoing PCI with BVS in de novo lesions both for ACS and stable heart disease. Mean age was 64 and 78% were men. In this group of patients, thrombosis frequency and clinical and angiographic characteristics were analyzed to determine the possible mechanisms involved.

Thrombosis occurred in 42 patients. Probable/definite thrombosis incidence was 1.8% at 30 days and 3% at 12 months with no differences across centers (p=0.60).

In 52% of cases, thrombosis presented as ST elevation AMI and 17% as sudden death.

Multivariable analysis of ostial lesions (p=0.049) and depressed ejection fraction (p=0.019) were independently associated to thrombosis.

hrombosis presented in 21% of patients that had stopped dual antiaggregation therapy, mostly before the first year. As regards angiographic variables, post procedural lower reference vessel and minimum lumen diameters were independent predictors of thrombosis (p<0.001).

These finding strongly suggest that underexpansion or incomplete malapposition could be the underlying mechanisms of thrombosis.

When implementing an implantation strategy, considering aggressive pre and post dilation with non-compliant balloons up to 0.5 mm larger than the BVS, thrombosis incidence dropped to 1%, which equals a 70% reduction in thrombosis incidence, when comparing both groups (p=0.012)

Conclusion
Thrombosis incidence in BVS is 3% at 12 months, though it could significantly reduce when using the adequate implantation strategy. Other thrombosis predictors were ostial lesions and depressed ventricular function, post procedural lower vessel and minimum lumen diameters. These last two findings suggest that the mechanism involved could be stent underexpansion.

Editorial Comment
This registry is not randomized and has a small number of events, which is why the mechanisms involved should be interpreted with caution. This study does not contemplate the use of intracoronary images for stent collocation, such as OCT.

Courtesy of Dr. Guillermo Migliaro.

 

Imagen: Abbott Vascular

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...